Nephrogenic systemic fibrosis: Center case review

Thomas C. Lauenstein, Khalil Salman, Roger Morreira, Sudha Tata, Dana Tudorascu, George Baramidze, Sareeta Singh-Parker, Diego R Martin

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

Purpose: To retrospectively analyze nephrogenic systemic fibrosis (NSF) cases at our center, to determine prior gadolinium based contrast agent (GBCA) administration and to evaluate possible common risk factors for the development of NSF by reviewing laboratory data and concurrent medications. Materials and Methods: A total of four data bases (pathology, MRI, dialysis, and medical records) were cross-referenced for identification and evaluation of NSF patients. Medical history of NSF patients was assessed as for previous deep venous thrombosis (DVT), surgery, or infections. Laboratory data (creatinine, anion gap, calcium, phosphorus, and albumin) as well as concurrent medication were evaluated. Findings were compared to those of a control group of non-NSF dialysis patients. Results: Between October 2003 and February 2007 a total of nine NSF cases were identified. All patients had undergone contrast-enhanced MRI prior to the diagnosis of NSF. Only one gadolinium chelate had been used at our MRI center (Omniscan®, gadodiamide; GE Healthcare). Of nine patients, eight were receiving dialysis at the time of the MRI scan. During the same time 312 dialysis patients received gadodiamide. Thus, the prevalence of NSF within dialysis patients exposed to gadodiamide was 2.6%. NSF patients presented with a higher creatinine and anion gap than the control patients. Other laboratory values as well as medication did not show a significant difference. There were no patterns regarding previous history of DVT, surgery, or infection in the NSF group. Conclusion: Our findings are consistent with the previously reported association between gadodiamide exposure and NSF. All NSF patients had severe renal insufficiency with glomerular filtration rate (GFR) < 30 (highest GFR = 25 mL/minute) at the time of last gadodiamide administration, and on average had received 71 mL of gadodiamide over an average of 2.9 administrations.

Original languageEnglish (US)
Pages (from-to)1198-1203
Number of pages6
JournalJournal of Magnetic Resonance Imaging
Volume26
Issue number5
DOIs
StatePublished - Nov 2007
Externally publishedYes

Fingerprint

Nephrogenic Fibrosing Dermopathy
gadodiamide
Dialysis
Acid-Base Equilibrium
Gadolinium
Glomerular Filtration Rate
Venous Thrombosis
Creatinine
Infection
Phosphorus
Contrast Media
Medical Records
Renal Insufficiency
Albumins

Keywords

  • Acidosis
  • Cofactors
  • Dialysis
  • Gadodiamide
  • Impaired renal function
  • Nephrogenic systemic fibrosis (NSF)

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Lauenstein, T. C., Salman, K., Morreira, R., Tata, S., Tudorascu, D., Baramidze, G., ... Martin, D. R. (2007). Nephrogenic systemic fibrosis: Center case review. Journal of Magnetic Resonance Imaging, 26(5), 1198-1203. https://doi.org/10.1002/jmri.21136

Nephrogenic systemic fibrosis : Center case review. / Lauenstein, Thomas C.; Salman, Khalil; Morreira, Roger; Tata, Sudha; Tudorascu, Dana; Baramidze, George; Singh-Parker, Sareeta; Martin, Diego R.

In: Journal of Magnetic Resonance Imaging, Vol. 26, No. 5, 11.2007, p. 1198-1203.

Research output: Contribution to journalArticle

Lauenstein, TC, Salman, K, Morreira, R, Tata, S, Tudorascu, D, Baramidze, G, Singh-Parker, S & Martin, DR 2007, 'Nephrogenic systemic fibrosis: Center case review', Journal of Magnetic Resonance Imaging, vol. 26, no. 5, pp. 1198-1203. https://doi.org/10.1002/jmri.21136
Lauenstein TC, Salman K, Morreira R, Tata S, Tudorascu D, Baramidze G et al. Nephrogenic systemic fibrosis: Center case review. Journal of Magnetic Resonance Imaging. 2007 Nov;26(5):1198-1203. https://doi.org/10.1002/jmri.21136
Lauenstein, Thomas C. ; Salman, Khalil ; Morreira, Roger ; Tata, Sudha ; Tudorascu, Dana ; Baramidze, George ; Singh-Parker, Sareeta ; Martin, Diego R. / Nephrogenic systemic fibrosis : Center case review. In: Journal of Magnetic Resonance Imaging. 2007 ; Vol. 26, No. 5. pp. 1198-1203.
@article{009dc6934b6e4eadac0125190059a8fc,
title = "Nephrogenic systemic fibrosis: Center case review",
abstract = "Purpose: To retrospectively analyze nephrogenic systemic fibrosis (NSF) cases at our center, to determine prior gadolinium based contrast agent (GBCA) administration and to evaluate possible common risk factors for the development of NSF by reviewing laboratory data and concurrent medications. Materials and Methods: A total of four data bases (pathology, MRI, dialysis, and medical records) were cross-referenced for identification and evaluation of NSF patients. Medical history of NSF patients was assessed as for previous deep venous thrombosis (DVT), surgery, or infections. Laboratory data (creatinine, anion gap, calcium, phosphorus, and albumin) as well as concurrent medication were evaluated. Findings were compared to those of a control group of non-NSF dialysis patients. Results: Between October 2003 and February 2007 a total of nine NSF cases were identified. All patients had undergone contrast-enhanced MRI prior to the diagnosis of NSF. Only one gadolinium chelate had been used at our MRI center (Omniscan{\circledR}, gadodiamide; GE Healthcare). Of nine patients, eight were receiving dialysis at the time of the MRI scan. During the same time 312 dialysis patients received gadodiamide. Thus, the prevalence of NSF within dialysis patients exposed to gadodiamide was 2.6{\%}. NSF patients presented with a higher creatinine and anion gap than the control patients. Other laboratory values as well as medication did not show a significant difference. There were no patterns regarding previous history of DVT, surgery, or infection in the NSF group. Conclusion: Our findings are consistent with the previously reported association between gadodiamide exposure and NSF. All NSF patients had severe renal insufficiency with glomerular filtration rate (GFR) < 30 (highest GFR = 25 mL/minute) at the time of last gadodiamide administration, and on average had received 71 mL of gadodiamide over an average of 2.9 administrations.",
keywords = "Acidosis, Cofactors, Dialysis, Gadodiamide, Impaired renal function, Nephrogenic systemic fibrosis (NSF)",
author = "Lauenstein, {Thomas C.} and Khalil Salman and Roger Morreira and Sudha Tata and Dana Tudorascu and George Baramidze and Sareeta Singh-Parker and Martin, {Diego R}",
year = "2007",
month = "11",
doi = "10.1002/jmri.21136",
language = "English (US)",
volume = "26",
pages = "1198--1203",
journal = "Journal of Magnetic Resonance Imaging",
issn = "1053-1807",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

TY - JOUR

T1 - Nephrogenic systemic fibrosis

T2 - Center case review

AU - Lauenstein, Thomas C.

AU - Salman, Khalil

AU - Morreira, Roger

AU - Tata, Sudha

AU - Tudorascu, Dana

AU - Baramidze, George

AU - Singh-Parker, Sareeta

AU - Martin, Diego R

PY - 2007/11

Y1 - 2007/11

N2 - Purpose: To retrospectively analyze nephrogenic systemic fibrosis (NSF) cases at our center, to determine prior gadolinium based contrast agent (GBCA) administration and to evaluate possible common risk factors for the development of NSF by reviewing laboratory data and concurrent medications. Materials and Methods: A total of four data bases (pathology, MRI, dialysis, and medical records) were cross-referenced for identification and evaluation of NSF patients. Medical history of NSF patients was assessed as for previous deep venous thrombosis (DVT), surgery, or infections. Laboratory data (creatinine, anion gap, calcium, phosphorus, and albumin) as well as concurrent medication were evaluated. Findings were compared to those of a control group of non-NSF dialysis patients. Results: Between October 2003 and February 2007 a total of nine NSF cases were identified. All patients had undergone contrast-enhanced MRI prior to the diagnosis of NSF. Only one gadolinium chelate had been used at our MRI center (Omniscan®, gadodiamide; GE Healthcare). Of nine patients, eight were receiving dialysis at the time of the MRI scan. During the same time 312 dialysis patients received gadodiamide. Thus, the prevalence of NSF within dialysis patients exposed to gadodiamide was 2.6%. NSF patients presented with a higher creatinine and anion gap than the control patients. Other laboratory values as well as medication did not show a significant difference. There were no patterns regarding previous history of DVT, surgery, or infection in the NSF group. Conclusion: Our findings are consistent with the previously reported association between gadodiamide exposure and NSF. All NSF patients had severe renal insufficiency with glomerular filtration rate (GFR) < 30 (highest GFR = 25 mL/minute) at the time of last gadodiamide administration, and on average had received 71 mL of gadodiamide over an average of 2.9 administrations.

AB - Purpose: To retrospectively analyze nephrogenic systemic fibrosis (NSF) cases at our center, to determine prior gadolinium based contrast agent (GBCA) administration and to evaluate possible common risk factors for the development of NSF by reviewing laboratory data and concurrent medications. Materials and Methods: A total of four data bases (pathology, MRI, dialysis, and medical records) were cross-referenced for identification and evaluation of NSF patients. Medical history of NSF patients was assessed as for previous deep venous thrombosis (DVT), surgery, or infections. Laboratory data (creatinine, anion gap, calcium, phosphorus, and albumin) as well as concurrent medication were evaluated. Findings were compared to those of a control group of non-NSF dialysis patients. Results: Between October 2003 and February 2007 a total of nine NSF cases were identified. All patients had undergone contrast-enhanced MRI prior to the diagnosis of NSF. Only one gadolinium chelate had been used at our MRI center (Omniscan®, gadodiamide; GE Healthcare). Of nine patients, eight were receiving dialysis at the time of the MRI scan. During the same time 312 dialysis patients received gadodiamide. Thus, the prevalence of NSF within dialysis patients exposed to gadodiamide was 2.6%. NSF patients presented with a higher creatinine and anion gap than the control patients. Other laboratory values as well as medication did not show a significant difference. There were no patterns regarding previous history of DVT, surgery, or infection in the NSF group. Conclusion: Our findings are consistent with the previously reported association between gadodiamide exposure and NSF. All NSF patients had severe renal insufficiency with glomerular filtration rate (GFR) < 30 (highest GFR = 25 mL/minute) at the time of last gadodiamide administration, and on average had received 71 mL of gadodiamide over an average of 2.9 administrations.

KW - Acidosis

KW - Cofactors

KW - Dialysis

KW - Gadodiamide

KW - Impaired renal function

KW - Nephrogenic systemic fibrosis (NSF)

UR - http://www.scopus.com/inward/record.url?scp=35848946598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35848946598&partnerID=8YFLogxK

U2 - 10.1002/jmri.21136

DO - 10.1002/jmri.21136

M3 - Article

C2 - 17969162

AN - SCOPUS:35848946598

VL - 26

SP - 1198

EP - 1203

JO - Journal of Magnetic Resonance Imaging

JF - Journal of Magnetic Resonance Imaging

SN - 1053-1807

IS - 5

ER -